Showing results (1321-1330 of 1,376) with videos related to

Sort By:
Pageof 138
Annals of Neurology|March 7, 2013
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J Darlington, Tarik Touil, Jean-Sebastien Doucet, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Neurology|April 6, 2011
Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionM Filippi, M A Rocca, F Camesasca, et al.
Scientific Reports|March 24, 2021
Evaluation of the gut microbiome in association with biological signatures of inflammation in murine polytrauma and shockSandra A Appiah, Christine L Foxx, Dominik Langgartner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthNicholas S Reed, James Russell Pike, Bharat Thyagarajan, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|May 10, 2024
Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled TrialMichael W Denham, Michelle L Arnold, Victoria A Sanchez, et al.
Science (New York, N.Y.)|February 27, 2025
Berkelium-carbon bonding in a tetravalent berkeloceneDominic R Russo, Alyssa N Gaiser, Amy N Price, et al.
Contemporary Clinical Trials|February 7, 2018
Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristicsPeter T Katzmarzyk, Corby K Martin, Robert L Newton, et al.
Pageof 138